Company: ZVRA
Filing Date: 2025-04-23
Form Type: DFAN14A
Source: 0000897069-25-000852
Chunk: 0

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-23
Form: DFAN14A
Chunk 0
---
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 _____________________________________ SCHEDULE 14A (RULE 14a-101)
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(AMENDMENT NO.) _____________________________________ Filed by the Registrant ☐Filed by a Party other than the Registrant ☒ Check the appropriate box:

| ☐                                                | Preliminary Proxy Statement                                                     |
| ☐                                                | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☐                                                | Definitive Proxy Statement                                                      |
| ☐                                                | Definitive Additional Materials                                                 |
| ☒                                                | Soliciting Material Under Rule 14a-12                                           |
| Zevra Therapeutics, Inc.                         |                                                                                 |
| (Name of registrant as specified in its charter) |                                                                                 |

DANIEL J. MANGLESS
TRAVIS C. MICKLE, PhD
ARTHUR C. REGAN
(Name of Person(s) Filing Proxy Statement, if other than the Registrant) -with copies to- Peter D. Fetzer Foley & Lardner LLP
777 East Wisconsin Avenue Milwaukee, WI 53202-5306 (414) 297-5596 Payment of Filing Fee (Check all boxes that apply):

| ☒ | No fee required                                                                                     |
| ☐ | Fee paid previously with preliminary materials                                                      |
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |

Proxy Communications Daniel J. Mangless has filed a preliminary proxy statement and accompanying BLUEproxy card with the U.S. Securities and Exchange Commission, to be used to solicit votes for the election of Travis C. Mickle, PhD and Arthur C. Regan to the Board of Directors of Zevra Therapeutics, Inc., a Delaware corporation (the “ Company”), at the Company’s 2025 Annual Meeting of Stockholders scheduled for May 29, 2025. Attached hereto are screenshots of posts on Stocktwits, a social media site, that Mr. Regan made between April 1, 2025 and April 10, 2025. Important Information These materials are not a solicitation of a proxy from any security holder of the Company. Daniel J.